The GIRAFE phase II trial on MVCT-based “volumes of the day” and “dose of the day” addresses when and how to implement adaptive radiotherapy for locally advanced head and neck cancer

We use cookies necessary to giving you a better online experience. By using our website you consent to all cookies in accordance with our Privacy Policy.